Concord Drugs Q2 Results
- BSE: 538965
- NSE: -
- ISIN: INE858L01010
- Sector: Biotechnology & Drugs
BSE
75.00
1.98 (2.71%)
1.98 (2.71%)Volume433.00
Updated: Fri 6 Mar, 2026 | 15:24:32
NSE
This stock is not traded on NSE
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
Quarter ended Sep 25
Note: Comparison is on QoQ basis
Quarterly - Concord Drugs Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 9.52 | 12.96 | -26.54% | 11.84 | -19.59% |
| Depreciation/ Amortization | 0.34 | 0.37 | -7.72% | 0.34 | -1.37% |
| Operating Income | 0.76 | 0.65 | 16.75% | 0.52 | 45.00% |
| Net Income | 0.19 | 0.12 | 63.61% | 0.04 | 343.32% |
| Other Operating Expenses Total | 0.37 | 0.29 | 28.39% | 0.41 | -9.74% |
| Net Income Before Taxes | 0.27 | 0.16 | 71.38% | 0.07 | 312.94% |
| Total Revenue | 10.28 | 13.61 | -24.48% | 12.36 | -16.86% |
| Selling/ General/ Admin Expenses Total | 1.09 | 0.89 | 23.54% | 0.93 | 17.21% |
| Diluted Normalized EPS | 0.19 | 0.12 | 58.33% | 0.04 | 375.00% |